Skip to content

Prospective single centre open-label study to collect real-world data on the safety and effectiveness of the Cochlear Nucleus CI632 Profile Plus Implant with Slim Modiolar electrode (CI632) as a treatment for bilateral moderate sloping to profound hearing loss in a Chinese population.

Prospective single centre open-label study to collect real-world data on the safety and effectiveness of the Cochlear Nucleus CI632 Profile Plus Implant with Slim Modiolar electrode (CI632) as a treatment for bilateral moderate sloping to profound hearing loss in a Chinese population.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076507
Enrollment
Unknown
Registered
2023-10-10
Start date
2023-01-11
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral moderate sloping to profound hearing loss

Interventions

Experimental group:Cochlear Nucleus CI632 Profile Plus Implant with Slim Modiolar electrode

Sponsors

Boao Super Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to No maximum

Inclusion criteria

Inclusion criteria: Subjects must meet all the inclusion criteria described below to be eligible for this clinical investigation: 1. Individuals aged 12 months and older at the time of consent with bilateral moderate sloping to profound sensorineural hearing loss. 2. Subjects identified as candidates for the CI632 at the Boao Super Hospital in Hainan Province. 3. Willing and able to provide written informed consent. For children, an authorised parent or guardian will provide written informed consent.

Exclusion criteria

Exclusion criteria: Subjects who meet any of the exclusion criteria described below will not be eligible for this clinical investigation. 1. Medical or psychological conditions that contraindicate undergoing cochlear implantation. 2. Evidence of retrocochlear conditions. 3. Unable or unwilling to comply with all the requirements of the clinical investigation as determined by the Investigator. 4. Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling. 5. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator. 6. Additional disabilities that may affect the subjects participation or safety during the clinical investigation. 7. Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation. 8. Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).

Design outcomes

Primary

MeasureTime frame
Pure-tone average aided thresholds (PTA4: 500,1000, 2000, and 4000 Hz) in the sound field at 6 months postactivation.;Safety will be measured by the incidence and severity of adverse events related to the device and program, as well as any serious adverse events unrelated to the device or program;

Secondary

MeasureTime frame
Pure-tone average aided thresholds (PTA4: 500,1000, 2000, and 4000 Hz) in the sound field at 6 months postactivation.;Subjective functional performance questionnaires (IT-MAIS)/MAIS/(SSQ-12 adults/SSQ-P parents);Evaluating Surgeons' Satisfaction with CI632 Implants through Surgeon Surveys;

Countries

China

Contacts

Public ContactXiguang Tian

Boao Super Hospital

esun@cochlear.com+86 136 1754 7272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026